Denotes a link to the speaker's bio page.
A scientist by training, Vivienne hosts medical programmes for Radio 4, writes widely on health, presents films, facilitates many high level conferences and debates and trains young researchers. She also has a part time role as head of engagement at Genomics England which is delivering the 100,000 Genomes Project. In September 2017 she was appointed to the board of UK Research & Innovation.
Nordic biobank initiatives: example FinnGen
Richard Rosenquist Brandell, Professor of Clinical Genetics Department of Molecular Medicine and Surgery, Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital. Project Leader, Genomics Medicine Sweden
Personalizing in Finland
The Norwegian Strategy for Personalised. Medicine in Healthcare
- Brief overview of the main areas covered by the strategy
- Update on ongoing actions to implement the strategy and what the Directorate of health has done so far
- Highlights from our “insight” survey among the public and relevant health personnel groups
- Perspectives for 2018
Nordic Alliance for Sequencing and Personalized Medicine
The Person in Personalized Medicine: Ethical and Societal Challenges
- The economy of anticipation: How promissory futures colonize the present
- Ethics on the ground in labs, clinics, and among patients and the public
- Societal challenges related to incidental findings, patient engagement, and public legitimacy
Investigating the opportunities for establishing a biomarker development infrastructure in Denmark.
New Concepts in Disease Classification – “Blood on the Tracks”
The use of Next Generation Sequencing (NGS) in pathology
The clinical demand for mutation detection within multiple genes from a single tumor sample requires molecular diagnostic laboratories to develop rapid, high-throughput, highly sensitive, accurate and parallel testing within tight budget constraints. To meet this demand, we implemented Next Generation Sequencing (NGS). As NGS opens the possibility for more extensive tumor profiling, this increases the opportunities for patients to access different drugs both in routine diagnostic setting but also in experimental diagnostic setting. The presentation gives an overview of the analyses performed in the laboratory.
Precision medicine takes into account individual variability in genes, environment, and lifestyle for each person. This approach allows prediction of treatment strategies of cancer patients. It is in contrast to a one-size-fits-all approach, and therefore the extent of analyses is grown to fulfil the aim of the optimal analytical answer for the patient.
Precision Medicine can Radically Improve Healthcare within the Next Decade:
- How Precision Medicine can reduce the use and cost of ineffective drugs
- New technical solutions to bridge the gap between DNA and diagnosis
- Single cell analysis
- Practical solutions for clinical translation
Overview of Norwegian clinical trial (MetAction study)...
Precision Medicine in Early Clinical Cancer Trials
The role of RWE in evidence generation
Precision Medicine: A data enabled reality
Regulated and unregulated data – how to get the most from both worlds.
- Digital Health Hub from Finland – a one-stopshop for regulated well-being data
- Market share of regulated health data compared to unregulated has started to decrease
- Unregulated data sits in silos and is hard to reach for researchers
- How to utilize data from decentralised services and create incentives for sharing
Patient-past Based Precision Medicine
Whilst cancer leads the way precision medicine is high on the agenda for rare diseases, diabetes, cardio and more. Hear about the latest breakthroughs and progress that is being made across disease:
NGS - applications in oncology. Cases where we have used NGS-based comprehensive genomic profiling on oncology patients. Johann will present and discuss what could be done with the results of such testing.
Johan Hartman, MD, PhD, Associate Professor in Pathology, Dept of Oncology-Pathology, Karolinska Institutet and University Laboratory
A new subclassification of type 2 diabetes steps towards precision medicine:
Leif will discuss the clinical consequences of a new subclassification of Type 2 diabetes (Ahlqvist E et al). Novel subgroups of adult-onset diabetes and their association with outcome: a datas-driven cluster analysis of six variables. Lancet Diabetes & Endocrinology, March 2, 2018.
This new sub-stratification might eventually help to tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes.
Prognostic Biomarkers Associated with Cardiovascular Events in Atrial Fibrillation:
Agneta Siegbahn, Professor Uppsala University, SciLifeLab
Designed to allow participants to deep-delve into specific topics, this session promotes open debate and helps formulate new strategies and partnerships.
Anne Mette Bang, Customer Engagement Manager, Cambio Healthcare Systems
Bobbie Ray-Sannerud, Program Director, Life Sciences research unit of DNV GL
Vibeke Binz Vallevik, Principal Researcher at the Life Sciences research unit of DNV GL
Nils Brünner, MD, DMSc, Co-Founder and Chairman of the Board, of Scandion Oncology A/S. Professor University of Copenhagen